Comparative analysis of the long-term surgical treatment results of noninvasive thymus gland tumors

Abstract

The study compared the long-term results of thymectomy from traditional “open” thoracic/sternotomic and endovideosurgical access in 98 patients with thymus tumors. All patients were divided into two groups depending on the thymectomies performed from various surgical approaches. The control group consisted of 34 patients in whom surgical interventions were performed via the traditional “open” access, and the main group consisted of 29 patients in whom surgical interventions were performed via the endovideosurgical access. Both groups were comparable by sex, age, concomitant pathology, presence, and severity of clinical signs of myasthenia gravis, tumor size, morphological structure, and progression stage according to the classifications by Masaoka-Koga (1997) and TNM-8 2017. According to the frequency of tumor recurrence and regression of myasthenic disorders within 3 years after surgery, no significant differences were found between the groups (2 (5.9%) and 0, p = 0.27;

9 (69.2%) and 10 (71.4%), p = 0.52, respectively). Moreover, no significantly significant differences were found in the long-term survival (so-called Kaplan–Meier survival function) between the two groups. The annual, 3-, 5- and 10-year survival rates in the control group were 100%, 90.3% ± 2%, 87% ± 4%, and 87% ± 4%, and in the video-assisted thymectomy group, the survival rates were 100%, 100%, 100%, and 92.3% ± 3%, respectively (p = 0.71). In general, the long-term results of endovideosurgical thymectomy with small tumors and the absence of invasion into neighboring anatomical structures do not differ from those of traditional “open” surgical interventions in terms of the main oncological indicators, namely, long-term survival and frequency of tumor recurrence. The obtained results are consistent with world literature data, according to which the most significant prognostic factor of long-term survival is the stage of tumor progression by TNM. The average 5-year survival rates following radical thymectomy were 90%, 90%, 60%, and 25%, respectively, for TNM stages I, II, III, and IV.

Keywords

thymus gland / thymoma / thymectomy / long-term results / endovideosurgery / generalized myasthenia gravis / survival function

References

[1] Nuraliev SM. Algoritm diagnostiki i khirurgicheskogo lecheniya zabolevanii vilochkovoi zhelezy i assotsiirovannykh s nimi sindromov [dissertation abstract]. Saint Petersburg; 2007. 26 p. (In Russ.).

[2] Нуралиев С.М. Алгоритм диагностики и хирургического лечения заболеваний вилочковой железы и ассоциированных с ними синдромов: автореф. дис. … канд. мед. наук. Санкт-Петербург, 2007. 26 с.

[3] Pishchik VG. Novoobrazovaniya sredosteniya: printsipy differentsial’noi diagnostiki i khirurgicheskogo lecheniya [dissertation abstract]. Saint Petersburg; 2008. 39 p. (In Russ.).

[4] Пищик В.Г. Новообразования средостения: принципы дифференциальной диагностики и хирургического лечения: автореф. дис. … д-ра мед. наук. Санкт-Петербург, 2008. 39 c.

[5] Kurganov IA, Bogdanov DIu. Role of miniinvasive techniques in the treatment of thymic diseases. Endoscopic Surgery. 2013;19(6):4954. (In Russ.).

[6] Курганов И.А., Богданов Д.Ю. Роль и место малоинвазивных хирургических технологий в лечении заболеваний вилочковой железы // Эндоскопическая хирургия. 2013. Т. 19, № 6. С. 49–54.

[7] Detterbeck FC. Evaluation and treatment of stage I and II thymoma. J Thorac Oncol. 2010;5(10S4):318–322. DOI: 10.1097/JTO.0b013e3181f20dab

[8] Detterbeck F.C. Evaluation and treatment of stage I and II thymoma // J Thorac Oncol. 2010. Vol. 5, No. 10S4. P. 318–322. DOI: 10.1097/JTO.0b013e3181f20dab

[9] Ruffini E, Venura F. Management of thymic tumors: a European perspective. J Thorac Dis. 2014;6(S2):228–237. DOI: 10.3978/j.issn.2072-1439.2014.04.19

[10] Ruffini E., Venura F. Management of thymic tumors: a European perspective // J Thorac Dis. 2014. Vol. 6, No. S2. P. 228–237. DOI: 10.3978/j.issn.2072-1439.2014.04.19

[11] Machaladze ZO, Davydov MI, Polotsky BE, et al. Thymic tumors. Vestnik RONTS im. N.N. Blokhina RAMN. 2008;19(1):47–58. (In Russ.).

[12] Мачаладзе З.О., Давыдов М.И., Полоций Б.Е., и др. Опухоли вилочковой железы // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2008. Т. 19, № 1. С. 47–58.

[13] Romanova TV, Belyakova MJ, Pushkin SJ, Reshetov A.P. Efficacy evaluation of thymectomy in myasthenia patients. Saratov Journal of Medical Scientific Research. 2009;5(2):234–237. (In Russ.).

[14] Романова Т.В., Белякова М.Ю., Пушкин С.Ю., Решетов А.П. Оценка эффективности тимэктомии пациентов с миастенией // Саратовский научно-медицинский журнал. 2009. Т. 5, № 2. С. 234–237.

[15] Sigal EI, Zhestkov KG, Burmistrov MV. Torakoskopicheskaya khirurgiya. Moscow: Dom knigi; 2012. 352 p. (In Russ.).

[16] Сигал Е.И., Жестков К.Г., Бурмистров М.В. Торакоскопическая хирургия. Москва: Дом книги, 2012. 352 с.

[17] Tomulescu V, Popescu I. Unilateral extended thoracoscopic thymectomy for nontumoral myasthenia gravis: a new standard. Semin Thorac Cardiovasc Surg. 2012;24(2):115–122. DOI: 10.1053/j.semtcvs.2012.06.003

[18] Tomulescu V., Popescu I. Unilateral extended thoracoscopic thymectomy for nontumoral myasthenia gravis: a new standard // Semin Thorac Cardiovasc Surg. 2012. Vol. 24, No. 2. P. 115–122. DOI: 10.1053/j.semtcvs.2012.06.003

[19] Tagawa T, Yamasaki N, Tsuchiya T, et al. Thoracoscopic versus transsternal resection for early stage thymoma: long-term outcomes. Surg Today. 2014;44:2275–2283. DOI: 10.1007/s00595-013-0829-5

[20] Tagawa T., Yamasaki N., Tsuchiya T., et al. Thoracoscopic versus transsternal resection for early stage thymoma: long-term outcomes // Surg Today. 2014. Vol. 44. P. 2275–2283. DOI: 10.1007/s00595-013-0829-5

[21] Dmitrochenko IV, Dzidzava II, Kotiv BN, et al. Comparative analysis of variants of surgical approach in treatment of thymic tumors (meta-analysis). Grekov’s Bulletin of Surgery. 2017;176(5):106–110. (In Russ.). DOI: 10.24884/0042-4625-2017-176-5-106-110

[22] Дмитроченко И.В., Дзидзава И.И., Котив Б.Н., и др. Сравнительный анализ вариантов хирургического доступа при лечении опухолей вилочковой железы (мета-анализ) // Вестник хирургии им. И.И. Грекова. 2017. Т. 176, № 5. С. 106–110. DOI: 10.24884/0042-4625-2017-176-5-106-110

[23] Chen G, Marx A, Chen W-H, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer. 2002;95(2):420–429. DOI: 10.1002/cncr.10665

[24] Chen G., Marx A., Chen W.-H., et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China // Cancer. 2002. Vol. 95, No. 2. P. 420–429. DOI: 10.1002/cncr.10665

[25] Huang J, Detterbeck FC, Wang Z, Loehrer PJ. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2010;5(12): 2017–2023. DOI: 10.1097/JTO.0b013e3181f13682

[26] Huang J., Detterbeck F.C., Wang Z., Loehrer P.J. Standard outcome measures for thymic malignancies // J Thorac Oncol. 2010. Vol. 5, No. 12. P. 2017–2023. DOI: 10.1097/JTO.0b013e3181f13682

[27] Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–350. DOI: 10.1016/j.critrevonc.2016.01.012

[28] Scorsetti M., Leo F., Trama A., et al. Thymoma and thymic carcinomas // Crit Rev Oncol Hematol. 2016. Vol. 99. P. 332–350. DOI: 10.1016/j.critrevonc.2016.01.012

[29] Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg. 1988;95(6): 1041–1047. DOI: 10.1016/S0022-5223(19)35673-9

[30] Nakahara K., Ohno K., Hashimoto J., et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients // J Thorac Cardiovasc Surg. 1988. Vol. 95, No. 6. P. 1041–1047. DOI: 10.1016/S0022-5223(19)35673-9

[31] Yagi K, Hirata T, Fukuse T, et al. Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded. Ann Thorac Surg. 1996;61(1):521–524. DOI: 10.1016/0003-4975(95)00983-3

[32] Yagi K., Hirata T., Fukuse T., et al. Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded // Ann Thorac Surg. 1996. Vol. 61, No. 1. P. 521–524. DOI: 10.1016/0003-4975(95)00983-3

[33] Ruffini E, Detterbeck F, Van Raemdonck D, et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2014;46(3):361–368. DOI: 10.1093/ejcts/ezt649

[34] Ruffini E., Detterbeck F., Van Raemdonck D., et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database // Eur J Cardiothorac Surg. 2014. Vol. 46, No. 3. P. 361–368. DOI: 10.1093/ejcts/ezt649

[35] Lucchi M, Mussi AJ. Surgical treatment of recurrent thymomas. Thor Oncol. 2010;5(10):348–351. DOI: 10.1097/JTO.0b013e3181f20f27

[36] Lucchi M., Mussi A.J. Surgical treatment of recurrent thymomas // Thor Oncol. 2010. Vol. 5, No. 10. P. 348–351. DOI: 10.1097/JTO.0b013e3181f20f27

[37] Bae MK, Lee SK, Lee JG, et al. Predictors of recurrence after thymoma resection. Yonsei Med J. 2014;54(4):875–882. DOI: 10.3349/ymj.2013.54.4.875

[38] Bae M.K., Lee S.K., Lee J.G., et al. Predictors of recurrence after thymoma resection // Yonsei Med J. 2014. Vol. 54, No. 4. P. 875–882. DOI: 10.3349/ymj.2013.54.4.875

[39] Detterbeck FC, Zeeshan A. Thymic tumors: a review of current diagnosis, classification, and treatment. Thoracic and Esophageal Surgery, 3rd edit. Philadelphia: Elsevier, 2008. P. 1589–1614. DOI: 10.1016/B978-0-443-06861-4.50134-9

[40] Detterbeck F.C., Zeeshan A. Thymic tumors: a review of current diagnosis, classification, and treatment. Thoracic and Esophageal Surgery, 3rd edit. Philadelphia: Elsevier, 2008. P. 1589–1614. DOI: 10.1016/B978-0-443-06861-4.50134-9

[41] Hamaji MA, Ali SO, Burt BM. Meta-analysis of surgical versus nonsurgical management of recurrent thymoma. Ann Thorac Surg. 2014;98(2):748–755. DOI: 10.1016/j.athoracsur.2014.04.028

[42] Hamaji M.A., Ali S.O., Burt B.M. Meta-analysis of surgical versus nonsurgical management of recurrent thymoma // Ann Thorac Surg. 2014. Vol. 98, No. 2. P. 748–755. DOI: 10.1016/j.athoracsur.2014.04.028

[43] Regnard J-F, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection:a series of 307 patients. J Thorac Cardiovasc Surg. 1996;112(2):376–384. DOI: 10.1016/S0022-5223(96)70265-9

[44] Regnard J.-F., Magdeleinat P., Dromer C., et al. Prognostic factors and long-term results after thymoma resection:a series of 307 patients // J Thorac Cardiovasc Surg. 1996. Vol. 112, No. 2. P. 376–384. DOI: 10.1016/S0022-5223(96)70265-9

[45] Quintanilla-Martinez L, Harris NL, Wilkins EW Jr, et al. Thymoma: histologic subclassification is an independent prognostic factor. Cancer. 1994;74(2):606–617. DOI: 10.1002/1097-0142(19940715)74:2<606::AIDCNCR2820740212>3.0.CO;2-T

[46] Quintanilla-Martinez L., Harris N.L., Wilkins E.W. Jr., et al. Thymoma: histologic subclassification is an independent prognostic factor // Cancer. 1994. Vol. 74, No. 2. P. 606–617. DOI: 10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T

[47] Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg. 1995;60: 908–914. DOI: 10.1016/0003-4975(95)00669-c

[48] Blumberg D., Port J.L., Weksler B., et al. Thymoma: a multivariate analysis of factors predicting survival // Ann Thorac Surg. 1995. Vol. 60. P. 908–914. DOI: 10.1016/0003-4975(95)00669-c

[49] Venuta F, Rendina EA, Percarmona EO, et al. Multimodality treatment of thymoma: a prospective study. Ann Thorac Surg. 1997;64(6):1585–1592. DOI: 10.1016/s0003-4975(97)00629-2

[50] Venuta F., Rendina E.A., Percarmona E.O., et al. Multimodality treatment of thymoma: a prospective study // Ann Thorac Surg. 1997. Vol. 64, No. 6. P. 1585–1592. DOI: 10.1016/s0003-4975(97)00629-2

[51] Geng Y, Zhang H, Wang Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients. A meta-analysis. Medcine. 2020;99(1):e18622. DOI: 10.1097/MD.0000000000018622

[52] Geng Y., Zhang H., Wang Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients. A meta-analysis // Medcine. 2020. Vol. 99, No. 1. ID e18622. DOI: 10.1097/MD.0000000000018622

[53] Margaritora S, Cesario A, Cusumano G, et al. Single-centre 40-year results of redo operation for recurrent thymomas. Eur J Cardiothorac Surg. 2012;40(4):894–901. DOI: 10.1016/j.ejcts.2011.01.025

[54] Margaritora S., Cesario A., Cusumano G., et al. Single-centre 40-year results of redo operation for recurrent thymomas // Eur J Cardiothorac Surg. 2012. Vol. 40, No. 4. P. 894–901. DOI: 10.1016/j.ejcts.2011.01.025

[55] Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol. 1994;12(6):1164–1168. DOI: 10.1200/JCO.1994.12.6.1164

[56] Loehrer P.J. Sr., Kim K., Aisner S.C., et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group // J Clin Oncol. 1994. Vol. 12, No. 6. P. 1164–1168. DOI: 10.1200/JCO.1994.12.6.1164

RIGHTS & PERMISSIONS

Eco-Vector